Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence

W. Kruis, V. Kardalinos, T. Eisenbach, M. Lukas, T. Vich, I. Bunganic, Juris Pokrotnieks, J. Derova, J. Kondrackiene, R. Safadi, D. Tuculanu, Z. Tulassay, J. Banai, A. Curtin, A. E. Dorofeyev, S. F. Zakko, N. Ferreira, S. Björck, M. M. Diez Alonso, J. MäkeläN. J. Talley, K. Dilger, R. Greinwald, R. Mohrbacher, R. Spiller

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

Background: Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. Aim: To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. Methods: Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left-sided diverticulitis. Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG-51, n=330). The primary endpoint was the proportion of recurrence-free patients during 48 weeks (SAG-37 and SAG-51) or 96 weeks (SAG-51) of treatment. Results: Mesalazine did not increase the proportion of recurrence-free patients over 48 or 96 weeks compared to placebo. In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo (P=.226). In SAG-51, the proportion of recurrence-free patients over 48 weeks was 46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo (P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1% respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one diverticulitis episode in the year prior to study entry had a lower recurrence risk compared to >1 episode. Safety data revealed no new adverse events. Conclusion: Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.

Original languageEnglish
Pages (from-to)282-291
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume46
Issue number3
DOIs
Publication statusPublished - Aug 2017
Externally publishedYes

Field of Science*

  • 3.1 Basic medicine
  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence'. Together they form a unique fingerprint.

Cite this